Fierce Pharma

OCTOBER 22, 2023

Lennon and McCartney. Simon and Garfunkel. Richards and Jagger. Padcev and Keytruda? Can the cancer-fighting duo rock on in bladder cancer? | The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy. The figures indicate that the combo can be transformative in the indication.

Chemotherapy 118

Chemotherapy 118

pharmaphorum

OCTOBER 22, 2023

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC Phil.

105

105

Fierce Pharma

OCTOBER 22, 2023

MADRID—Attendees for the European Society for Medical Oncology Congress 2023 arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitem | ESMO attendees arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitement of an industry conference that promised to showcase breakthroughs in breast, lung and prostate cancer.

105

105

Med Ed 101

OCTOBER 22, 2023

Vitamin B12 is a critical nutrient that helps with the function of major body systems. It is involved in the production of red blood cells, is important in energy production, and helps maintain a normally functioning nervous system. Vitamin B12 deficiency can lead to anemia, fatigue, weakness, numbness, tingling, and cognitive impairments. Permanent nerve damage […] The post Drugs That Cause Vitamin B12 Deficiency – Top 5 appeared first on Med Ed 101.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

OCTOBER 22, 2023

Novartis has high hopes for its radiotherapy Pluvicto. | As Novartis aims to move its radiotherapy Pluvicto into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that cast a cloud of uncertainty over its regulatory path forward.

97

97

pharmaphorum

OCTOBER 22, 2023

ESMO: Opdivo chases Keytruda in perioperative lung cancer Phil.

68

68

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs. Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively.

Vaccines 40

Vaccines 40

BioPharm

OCTOBER 22, 2023

Sterile filtration is essential within many steps of a bioprocessing operation, both upstream and downstream, ensuring the biopharmaceutical product’s proper performance, safety, and quality. When seeking to maximize filtration efficiency, it helps to understand how sterile filtration and single-use systems work together, as well as how optimizing the filter design for specific applications can enhance performance.

40

40

The Guardian - Pharmaceutical Industry

OCTOBER 22, 2023

Fantastic Beasts director David Yates’s true-life big pharma scandal is carried by the British actor ​​playing a money-hungry drug rep David Yates takes time out from being the in-house director of the Fantastic Beasts films with a formulaic, factually based drama on a subject that has already been thoroughly explored by other, more serious-minded movies, documentaries and television series: America’s opioid crisis and the cynical workings of big pharma.

49

49

BioPharm

OCTOBER 22, 2023

There are many reasons behind the success of a technology transfer. But at the center of this complexity is one critical role: project management in the tech transfer.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

OCTOBER 22, 2023

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.   Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan.

136

136